HC 1102
Alternative Names: Apalutamide analogue - Hinova Pharmaceuticals; ARN-509 analogue - Hinova Pharmaceuticals; HC1102Latest Information Update: 28 Oct 2021
At a glance
- Originator Hinova pharmaceuticals
- Class Antiandrogens; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer; Triple negative breast cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Prostate-cancer in China (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in China (PO)